Target
CD38
1 product
46 abstracts
Abstract
Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).Org: University of Lille, CHU Lille - Hopital Huriez, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Service d'Hématologie et Thérapie Cellulaire,
Abstract
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).Org: Princess Margaret Cancer Centre, Ankara University, University Hospital Brno, General Hospital Evangelismos, Athens, Greece, St. Vincent's Hospital Melbourne,
Abstract
All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D.Org: Centre Hospitalier Universitaire de Nantes, Centre Hospitalier Universitaire de Poitiers, Vendée Departmental Hospital Centre, Hopital Cote de Nacre, Hematology Department, University Cancer Institute IUCT oncopôle, Toulouse, France,
Abstract
Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).Org: Centre Hospitalier Universitaire de Nantes, Ankara University, University of Athens, School of Medicine, Showa University, Memorial Sloan Kettering Cancer Center,
Abstract
Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).Org: Université de Poitiers et Centre Hospitalier Universitaire de Poitiers, INSERM U1313 and CIC 1082, Poitiers, France, Hôpital Haut Leveque, University Hospital, Pessac, France, ECSTRA, Centre de Recherche en Epidémiologie et Statistiques, INSERM UMR 1153, Paris, France, Lille University Hospital, Lille, France, CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France,
Abstract
Long-term follow-up of ARI0002h (cesnicabtagene autoleucel), an academic point-of-care B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell strategy: Activity and safety after fractionated initial therapy and booster dose in 60 patients with relapsed/refractory multiple myeloma (RRMM).Org: IMIB-Pascual Parrilla, University of Murcia, Complutense University, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Biomedicina de Sevilla (IBIS)/CSIC,
Abstract
A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis.Org: Boston University Section of Hematology and Medical Oncology,
Abstract
Rapid reduction of free light chains and improvement in renal outcomes in patients with newly diagnosed multiple myeloma admitted with acute kidney injury with daratumumab-based therapy and without plasmapheresis.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA,
Abstract
Effect of daratumumab on light chain reduction in newly diagnosed multiple myeloma with light chain cast nephropathy.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC,
Abstract
Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma.Org: Myeloma Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, New York, NY, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
Analysis of real-world (RW) pomalidomide (pom) dosing patterns in patients (pts) with multiple myeloma (MM) from the Flatiron database.Org: Myeloma, Waldenstrom’s and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy,
Abstract
Efficacy of carfilzomib-based regimens as induction/consolidation therapy in newly diagnosed multiple myeloma: A meta-analysis.Org: Albany Medical Center Hospital, JT Mather/Northwell Health,
Abstract
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.Org: University College London Cancer Institute, University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Medical College of Wisconsin, Peter MacCallum Cancer Centre, Melbourne, Australia, Hematology Clinic,
Abstract
Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.Org: Vanderbilt University Medical Center, University Hospital of Salamanca, Helen Diller Family Comprehensive Cancer Center, Princess Margaret Cancer Centre, Levine Cancer Institute/Atrium Health,
Abstract
Treatment patterns for extramedullary multiple myeloma and outcomes with CAR-T therapy and bispecific antibodies.Org: Mayo Clinic, Mayo Clinic (Rochester, MN), Mayo Clinic Department of Pediatric and Adolescent Medicine, Division of Hematology, Mayo Clinic, Rochester, MN,
Abstract
Open label single arm study to assess the implementation of home based daratumumab administration in patients being treated for multiple myeloma.Org: Sidney Kimmel Cancer Center at Thomas Jefferson University, Thomas Jefferson University Hospital, Thomas Jefferson University,
Abstract
Patient-derived MicroOrganoSpheres (MOS) and precision clinical decision-making for patients with multiple myeloma.Org: Xilis.Inc, Durham Veteran Affairs Medical Center, NC Medical Research, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Xilis, Inc.,
Abstract
Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data.Org: Samuel Oschin Comprehensive Cancer Center, Department of Hematology, Mayo Clinic Rochester, Janssen Global Market Access, Janssen Scientific Affairs, Georgetown University Medical Center,
Product
TMZAbstract
Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).Org: Medical College of Wisconsin, Milwaukee, Froedtert & Medical College of Wisconsin, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, University of Arkansas Medical Sciences,
Abstract
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.Org: Anaveon, Institute of Medical Oncology, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Lillebaelt Hospital, University Hospital of Southern Denmark,
Abstract
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.Org: Memorial Sloan Kettering Cancer Center, MSKCC, Myeloma Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Adult Bone Marrow Transplant Service,
Abstract
MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).Org: Department of Hematology and Cancer Prevention, Medical University of Silesia, Katowice, Poland, China Medical University Hospital, Taichung, Taiwan, Division of Hematology, National Taiwan University Hospital, Taipei, Taiwan, Seoul National University Hospital, Seoul, South Korea, Pfizer Inc., New York, NY, Pfizer SLU, Madrid, Spain,
Abstract
Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).Org: Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Vrije Universiteit Amsterdam, Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Levine Cancer Institute/Atrium Health, Charlotte, NC,
Abstract
ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM).Org: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Myeloma, Memorial Sloan Kettering Cancer Center, Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan,
Abstract
EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Org: Winship Cancer Center of Emory University, St. Vincent’s Hospital, University of Melbourne, National and Kapodistrian University of Athens, Clínica Universidad de Navarra and CIBEREHD,
Abstract
A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency.Org: Emory University School of Medicine and Winship Cancer Institute, UPMC Cancer Center - Hillman Cancer Center, Winship Cancer Institute of Emory University,
Abstract
CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.Org: Mayo Clinic, Sarah Cannon Transplant and Cellular Therapy Program, Genentech, F. Hoffmann-La Roche Ltd,
Abstract
Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A real-world observational chart review study.Org: RTI Health Solutions, Pfizer Inc., London, United Kingdom,
Abstract
A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health,
Abstract
Real-world data on incidence of acute adverse reactions (AARs) reported in clinical practice.Org: Medical Day Hospital Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Day Hospital Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Pharmacy Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori-University of Milan,
Abstract
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission.Org: University of Chicago Medical Center, Chicago, IL, Center for Data Intensive Science at the University of Chicago, University of Chicago,
Abstract
A novel risk assessment metric for antimyeloma therapies and drug interactions.Org: Kansas State University–Olathe, DATA Consortium, Computational Comparative Medicine, Department of Mathematics, Università degli Studi di Genova, San Martino, Italy, Myeloma Program,
Abstract
Management and outcomes of advanced stage cardiac AL amyloidosis in the daratumumab era.Org: University of California, San Diego Center for Advanced Laboratory Medicine,
Abstract
Association of venetoclax-based therapy with increased survival in multiple myeloma (MM) harboring t(11;14): A single-center experience.Org: H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine,
Abstract
Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies.Org: Massachusetts College of Pharmacy and Health Sciences, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Division of Hematology and Oncology,
Abstract
CAR-T cells targeting CD38 and LMP1 and anti-tumor activity against NK/T cell lymphoma.Org: The First Affiliated Hospital of Zhengzhou University, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Cytology-histology correlation, time to diagnosis and time to therapy when cytology is performed in addition to biopsies in malignant spinal lesions of previously unknown malignant disease.Org: Department of Oncology, Haematology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Department of Orthopedics and Trauma Surgery, Section for Spine Surgery, University Hospital Hamburg Eppendorf, Hamburg, Germany, Institute of Pathology, University Hospital Hamburg Eppendorf, Hamburg, Germany, RKH Orthopädische Klinik Markgröningen gGmbH, Markgröningen, Germany, Department of Orthopedics and Trauma Surgery, University Hospital Hamburg Eppendorf, Hamburg, Germany,
Abstract
Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.Org: Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, University Federico II, Cimitile, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST (IRCCS) s,
Abstract
Real-world analysis of D-RVd v. RVd at induction for newly diagnosed transplant eligible multiple myeloma patients.Org: HealthTree Foundation, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT,
Abstract
Association of SARS-CoV-2 vaccinations and personal protective measures with seroconversion and risk of infection in a large real-world cohort of patients with cancer.Org: DKFZ-Hector Cancer Institute and Department of Personalized Oncology, University Medical Center Mannheim, Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), German Center for Lung Research (DZL),
Abstract
Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment.Org: Vanderbilt University Medical Center, Hematology Department, Hospital Universitari i Politècnic La Fe, CHU Nantes-Department of Hepato-Gastroenterology, University of North Carolina School of Medicine, University of Wisconsin Health,
Abstract
Outcomes of patients with multiple myeloma refractory to different administration schedules of bortezomib.Org: Mayo Clinic,
Abstract
Clinical outcomes of patients with multiple myeloma following disease progression after BCMA-targeted CAR T-cell therapy.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, UT Health Sciences Center at Houston, University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Incidence of second primary malignancies (SPMs) in patients with multiple myeloma (MM) receiving anti-CD38 monoclonal antibodies (mAbs): A systematic review and meta-analysis.Org: Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, Massachusetts General Hospital, Boston, MA, USA, The University of Arizona, Tucson, AZ, Faculty of Health Sciences, Hamilton, ON, Canada,